Oligonucleotide (Antisense oligonucleotide) · Gene silencing: dystrophin (DMD) pre-mRNA (DMD) · developed by Sarepta Theraps
Eteplirsen is an antisense oligonucleotide that binds exon 51 of dystrophin pre-mRNA, causing that exon to be excluded during mRNA processing. It is intended to allow production of an internally truncated dystrophin protein in patients with mutations amenable to exon 51 skipping. It is studied in Duchenne muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 13, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03992430 | Phase 3 | Muscular Dystrophy, Duchenne | Completed | SRPT |
| NCT04179409 | Phase 2 | Duchenne Muscular Dystrophy | Completed | SRPT |
| NCT01540409 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | Completed | SRPT |
| NCT00844597 | Phase 1/2 | Duchenne Muscular Dystrophy | Completed | SRPT |
| NCT00159250 | Phase 1/2 | Duchenne Muscular Dystrophy | Completed | SRPT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)Muscular Dystrophy, Duchenne
Updated Nov 15, 2026. Something wrong or missing? Report it on the SRPT page.
See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRPT catalysts and pipeline →